3/13
01:06 pm
crvs
Corvus Pharmaceuticals (CRVS) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $33.00 price target on the stock, up from $32.00.
Low
Report
Corvus Pharmaceuticals (CRVS) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $33.00 price target on the stock, up from $32.00.
3/13
12:55 pm
crvs
Rating for CRVS
Low
Report
Rating for CRVS
3/13
12:55 pm
crvs
Rating for CRVS
Low
Report
Rating for CRVS
1/22
03:22 pm
crvs
Rating for CRVS
Low
Report
Rating for CRVS
1/22
03:22 pm
crvs
Rating for CRVS
Low
Report
Rating for CRVS
1/21
12:58 pm
crvs
Rating for CRVS
Medium
Report
Rating for CRVS
1/21
12:58 pm
crvs
Rating for CRVS
Medium
Report
Rating for CRVS
1/21
09:27 am
crvs
Rating for CRVS
Low
Report
Rating for CRVS
1/21
09:27 am
crvs
Rating for CRVS
Low
Report
Rating for CRVS
1/20
04:06 pm
crvs
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Medium
Report
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
1/20
12:05 pm
crvs
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
High
Report
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "buy" rating reaffirmed by analysts at HC Wainwright.